knowledge -WSS

knowledge

author：Wikipedia 2025-09-03 09:37:01 - browse：951

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Community Health Systems hospitals under DOJ investigation

WSS

The CDC's new social media misinformation war

Medicare inequities exacerbate Puerto Rico’s health disparities

With competition flaring, obesity drug hits goal in liver disease study

With competition flaring, obesity drug hits goal in liver disease study

A single Democrat is willing to weaken Medicare negotiation power

Cano Health’s bankruptcy is a warning for Medicare Advantage

entertainment

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

hotspot

Jerome Adams on the need for new antivirals for Covid

Medicare Advantage plans can’t deny care with AI, CMS warns

United colonoscopy coverage change 'may cost lives,' doctors say

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Cancer drug shortages should be causing more outrage

Gene therapy for Afghan refugees’ infant will be fully covered

Apple is now the first public company to be valued at $3 trillion

The Biogen Aduhelm mess could happen again

Medicare details structure of new drug price negotiation program

Antivenom research: Lessons from HIV applied in search for universal antidote

hotspot

In utero gene editing: an explainer

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

He's a Nobel laureate. Critics say he was misleading on Covid

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Texas Medical Board asked to define abortion emergency exception

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

leisure time

focus

focus

explore